Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
This clinical trial (ChiCTR1800019185) is designed to be an open-label, prospective, single-center, single arm exploratory research study. The study will recruit non-small cell lung cancer patients (NSCLC) with slow progression after first-line treatment with EGFR-TKI drugs. Slow progression will be confirmed by the presence of serum carcinoembryonic antigen or imaging evaluation. The primary aim is to assess progression-free survival after EGFR-TKIs treatment combined with apatinib 250 mg once daily. The secondary objectives are to evaluate objective efficacy, disease control rates, quality of life, overall survival, and safety. From September 2018 to September 2020, under specific entry and discharge standards, we plan to enroll 38 eligible patients until the end of the study. We hope that our study will help to explore a new way of combining the small molecular inhibitors of antiangiogenesis with EGFR-TKIs to overcome acquired drug resistance.
['Li|Xin|X|', 'Liu|Minghui|M|', 'Zhang|Hongbing|H|', 'Liu|Hongyu|H|', 'Chen|Jun|J|0000-0002-2362-5359']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D000971:Antineoplastic Combined Chemotherapy Protocols D002289:Carcinoma, Non-Small-Cell Lung D043844:Crown Ethers D018450:Disease Progression D019008:Drug Resistance, Neoplasm D066246:ErbB Receptors D000069347:Erlotinib Hydrochloride D005260:Female D005500:Follow-Up Studies D000077156:Gefitinib D006801:Humans D008175:Lung Neoplasms D008297:Male D008875:Middle Aged D009154:Mutation D011379:Prognosis D011446:Prospective Studies D011725:Pyridines D011799:Quinazolines D012107:Research Design D055815:Young Adult
Apatinib EGFR-TKIs non-small cell lung cancer slow progression